Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent

Autor:	S.K. Esub Basha, Venu Sampath Kumar Golla, K Shreyas Chandra, R.K. Ramachandra, P Likitha, Chirravuri S. Phani Kumar, Sai Kiran S.S. Pindiprolu
Rok vydání:	2020
Předmět:	0301 basic medicine Drug medicine.drug_class viruses media_common.quotation_subject Pneumonia Viral Antibiotics Pharmacology medicine.disease_cause Antiviral Agents Article Betacoronavirus 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine parasitic diseases medicine Humans Lung Pandemics Salinomycin Repurposing Pyrans Coronavirus media_common Drug Carriers SARS-CoV-2 business.industry Drug Repositioning COVID-19 Cancer General Medicine medicine.disease Lipids Endocytosis Nanostructures COVID-19 Drug Treatment Drug repositioning 030104 developmental biology chemistry RNA Viral Coronavirus Infections Drug carrier business ACE-2 030217 neurology & neurosurgery
Zdroj:	Medical Hypotheses
ISSN:	0306-9877
DOI:	10.1016/j.mehy.2020.109858
Popis:	Coronavirus disease outbreak caused a severe public health burden all over the world. Salinomycin (SAL) is a broad-spectrum antibiotic that had drawn attention in selective targeting of cancer and viral infections. Recent drug screen identified SAL as a potent antiviral agent against SARS-CoV-2. In this hypothesis, we discuss the potential of pulmonary delivery of SAL using nanostructured lipid carriers (NLCs) against SARS-CoV-2.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b83bb4293e64d1d7dee347d574212928 https://doi.org/10.1016/j.mehy.2020.109858 Zobrazit plný text záznamu Full Text from ScienceDirect